AART C-02-60

Research Title: Anecortave Acetate Risk-Reduction Trial (AART)

Sponsor: Allergan

Principal Investigator: Atul Sharma, M.D.

Description: A 48-month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months.

Start Date: March 2006

Recruitment: Completed

Project Personnel: Leslie Marcus, CCRC

Location(s): Riverdale; 155 Medical Way, Suite E, Riverdale, GA 30274